Oncolytic virus bispecific gene delivery for high grade gliomas
用于高级别神经胶质瘤的溶瘤病毒双特异性基因递送
基本信息
- 批准号:10832350
- 负责人:
- 金额:$ 36.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AntigensBiological ProductsCancer BurdenCancer ModelCellsChildhoodClinical TrialsCombination immunotherapyComplementCytometryDataData SetDevelopmentDrug ModulationEffectivenessFundingFutureGene DeliveryGenomic approachGenomicsGliomaGoalsHybridsImmuneImmune responseImmunologic MonitoringImmunotherapyKnowledgeMalignant Childhood NeoplasmMalignant NeoplasmsMinnesotaModalityMutationMyeloid-derived suppressor cellsNatural ImmunityNatural Killer CellsNew YorkOhioOncolytic virusesPatientsPediatric HospitalsProteinsRegimenResistanceResource SharingSiteTechnologyTestingTherapeuticUniversitiesVirusadaptive immunityanti-tumor immune responsecancer cellcancer immunotherapychimeric antigen receptor T cellsconventional therapydata integrationeffective therapyimmunogenicityimmunotherapy clinical trialsimprovedmedical schoolsnovelpre-clinicalrational designresponsesmall moleculesynergismtranscriptomicstumor-immune system interactions
项目摘要
Overall Center Abstract
This application describes the Pediatric Ohio-New York Cancer (Peds-ONC) Immunotherapy Center, created in
response to the RFA as a second nidus for the Pediatric Immunotherapy Discovery and Development
Consortium (PI-DDN). To complement the funded U54 (Maris and Mackall, MPI) of the PI-DDN that largely
seeks to harness adaptive immunity to further develop CAR-T cells against newly identified antigens, we propose
to harness innate immunity to target pediatric cancers, to circumvent resistance to conventional therapy, and to
further enable adaptive/hybrid immune approaches.
Our aims are to (1) Identify and overcome barriers to utilizing NK and CAR-NK cells as cancer therapeutics, (2)
break tolerance to “self” cancer-associated proteins and (3) enhance immunotherapies by targeting suppressive
myeloid cells. We will accomplish our aims through four projects, based at two major sites based in Ohio
(Nationwide Children’s Hospital) and New York (New York Medical College) with subsites in Columbus (The
Ohio State University) and Minneapolis (Univeristy of Minnesota). In addition to an Administrative Shared
Resource (Core A, directed by Dr. Timothy Cripe and Associate Director Dr. Mitchell Cairo), the projects are
scientifically supported by a comprehensive Genomics & Immune Monitoring Shared Resource (Core B, directed
by Dr. Elaine Mardis with several subspecialy assistant directors). Core B provides integrated datasets via state-
of-the-art technologies including mass cytometry, single cell transcriptomics, and an array of other genomics
approaches that enable detailed characterizations and tracking of cancer cell immunogenicity, the tumor immune
microenvironment, and immunologic responses. We have also assembled strong external and internal scientific
advisory boards of renowned leaders whose expertise spans the projects and shared resources. The projects
are highly integrated and cross-informative. We propose that therapeutic regimens that combine modalities will
produce synergy that drives anti-tumor immune responses in preclinical pediatric cancer models, overcoming
the limitations of low mutational burdens. Our goal is to generate a sufficient body of knowledge with compelling
data to inform the rational design of future clinical trials and thereby improve the lives of children with cancer.
1
总体中心
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TIMOTHY P CRIPE其他文献
TIMOTHY P CRIPE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TIMOTHY P CRIPE', 18)}}的其他基金
Project 4:Targeting M2-like Macrophages and MDSC with Myelolytic-Virotherapy
项目 4:利用溶髓病毒疗法靶向 M2 样巨噬细胞和 MDSC
- 批准号:
10885260 - 财政年份:2023
- 资助金额:
$ 36.69万 - 项目类别:
Project 4:Targeting M2-like Macrophages and MDSC with Myelolytic-Virotherapy
项目 4:利用溶髓病毒疗法靶向 M2 样巨噬细胞和 MDSC
- 批准号:
10885263 - 财政年份:2023
- 资助金额:
$ 36.69万 - 项目类别:
Novel Immunomodulation and Facilitation of “Suppression Proof” CAR NK cell against Ewing sarcoma
新型免疫调节和促进“抑制证明”CAR NK 细胞对抗尤文肉瘤
- 批准号:
10834579 - 财政年份:2023
- 资助金额:
$ 36.69万 - 项目类别:
Training Program in Basic and Translational Pediatric Oncology Research
基础和转化儿科肿瘤学研究培训计划
- 批准号:
10408197 - 财政年份:2022
- 资助金额:
$ 36.69万 - 项目类别:
Overcoming Immunological Tumor Microenvironment Resistance in Ewing Sarcoma
克服尤文肉瘤的免疫肿瘤微环境耐药性
- 批准号:
10616121 - 财政年份:2022
- 资助金额:
$ 36.69万 - 项目类别:
Training Program in Basic and Translational Pediatric Oncology Research
基础和转化儿科肿瘤学研究培训计划
- 批准号:
10590705 - 财政年份:2022
- 资助金额:
$ 36.69万 - 项目类别:
IL1RAP CAR NK cells enhance targeting of Ewing Sarcoma (ES) alone and with combinatorial targeted immunotherapy
IL1RAP CAR NK 细胞单独或联合靶向免疫疗法可增强对尤文肉瘤 (ES) 的靶向作用
- 批准号:
10401167 - 财政年份:2021
- 资助金额:
$ 36.69万 - 项目类别:
相似海外基金
Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products.
加强监管系统和标准化活动方面的合作,以增加全球获得安全有效的生物产品的机会。
- 批准号:
10448926 - 财政年份:2021
- 资助金额:
$ 36.69万 - 项目类别:
Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products.
加强监管系统和标准化活动方面的合作,以增加全球获得安全有效的生物产品的机会。
- 批准号:
10491861 - 财政年份:2021
- 资助金额:
$ 36.69万 - 项目类别:
Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products.
加强监管系统和标准化活动方面的合作,以增加全球获得安全有效的生物产品的机会。
- 批准号:
10675535 - 财政年份:2021
- 资助金额:
$ 36.69万 - 项目类别:
EPSRC Centre for Doctoral Training in Bioprocess Engineering Leadership (Complex Biological Products Manufacture)
EPSRC 生物过程工程领导力博士培训中心(复杂生物制品制造)
- 批准号:
EP/S021868/1 - 财政年份:2019
- 资助金额:
$ 36.69万 - 项目类别:
Training Grant
Exploring interactions and benefits of novel microbial biological products in blueberry propagation
探索新型微生物生物制品在蓝莓繁殖中的相互作用和益处
- 批准号:
529840-2018 - 财政年份:2018
- 资助金额:
$ 36.69万 - 项目类别:
Applied Research and Development Grants - Level 1
GOALI: Collaborative Research: Industrial Implementation of Smart Biopolymers for Purification of Biological Products
目标:合作研究:用于生物制品纯化的智能生物聚合物的工业实施
- 批准号:
1403724 - 财政年份:2014
- 资助金额:
$ 36.69万 - 项目类别:
Standard Grant
GOALI: Collaborative Research: Industrial Implementation of Smart Biopolymers for Purification of Biological Products
目标:合作研究:用于生物制品纯化的智能生物聚合物的工业实施
- 批准号:
1403697 - 财政年份:2014
- 资助金额:
$ 36.69万 - 项目类别:
Standard Grant
Formulation and delivery approaches for water soluble biological products delivered through the skin focussing on L-Ascorbic Acid.
通过皮肤输送的水溶性生物产品的配方和输送方法,重点是 L-抗坏血酸。
- 批准号:
131690 - 财政年份:2014
- 资助金额:
$ 36.69万 - 项目类别:
Feasibility Studies
Formulation and stability of biological products for skin delivery focussing on Retinol.
以视黄醇为重点的皮肤输送生物制品的配方和稳定性。
- 批准号:
131338 - 财政年份:2013
- 资助金额:
$ 36.69万 - 项目类别:
Feasibility Studies
Demonstrate the effectiveness of antimicrobial protection of new types of Biological Products
展示新型生物制品抗菌保护的有效性
- 批准号:
429734-2011 - 财政年份:2012
- 资助金额:
$ 36.69万 - 项目类别:
Experience Awards (previously Industrial Undergraduate Student Research Awards)